In addition to encouraging patients to work with a physician to develop a treatment plan, the exhibit offers opportunities to register for Thinking Forward(TM), a support program that provides free information, resources, and practical advice for people with bipolar depression
While lithium and several antiepileptic and antipsychotic agents are currently used to treat either manic or mixed episodes of BPD, only Eli Lilly's Symbyax and AstraZeneca's Seroquel have received FDA approval for treatment of bipolar depression
MONTREAL -- Primary care physicians are not confident when it comes to diagnosing and managing patients with bipolar depression
, according to a cross-sectional survey of providers participating in a national electronic health record database.
This increase in operating expenses of $787,000 was primarily the result of increased spending associated with advancement of both our Phase 3 clinical trial of RG1068 for pancreatic imaging, and our Phase 2b clinical trial of RG2417 for bipolar depression
, as well as increased research and development expenses associated with our preclinical HDAC inhibitor program for Friedreich's ataxia.
com/reports/c42440) has announced the addition of the new report from Datamonitor "Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression
Set to Drive Near-term Growth" to their offering.
Unipolar and bipolar depression
are not associated with any major deficit in the sensory aspects of gustatory and olfactory function or altered hedonic ratings of chemosensory stimuli, a Polish study shows.
Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression
, According to a New Report from Decision Resources
Chapter 11 Diagnostic and Clinical Management Approaches to Bipolar Depression
, Bipolar II and their Comorbidities (Giulio Perugi, S.
Antidepressants that work fairly well for "vanilla" unipolar depression are ineffective for bipolar depression
, he said.
1) This online survey was commissioned by the National Council for Community Behavioral Healthcare and AstraZeneca to better understand the impact of bipolar depression
on people's lives.
He led the efforts resulting in the launch and/or product lifecycle of several important neuroscience products, including the antidepressant Prozac, Strattera for attention-deficit (ADHD), Symbyax for bipolar depression
, Cymbalta for major depression/ neuropathic pain, and the psychotropic Zyprexa (including a series of line extensions).
Authors looked at five randomized, controlled trials comparing lamotrigine with placebo for treatment of bipolar depression